What We Do

Icentia is a combined medical devices and service company based in Canada. It aims at providing a line of innovative medical testing solutions for healthcare institutions. Thanks to a strong understanding of the institutional healthcare environment along with important partnerships with medical specialists, Icentia is able to offer valuable solutions for major problems in the fields of medical testing.

Our mission is to help healthcare institutions become more efficient by providing unique solutions easing the process of medical testing.

Icentia has put together a seasoned management team with solid expertise in medical device development, global supply chain management, and operations in a regulated environment.

Icentia benefits from a collaboration with the Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ) for the testing of its products. IUCPQ is one of the largest centers for cardiology and pulmonology in eastern Canada.

Our Corporate Values

What Drives our Decisions

These values define us as a company not only for our clients and partners, but also for patients who benefit from our technologies. Our values describe who we are and how we do things.

Our Leadership Team

martin leblanc
CHAIRMAN OF THE BOARD

Martin is the co-founder and was appointed as Vice-Chairman of CellCarta Biosciences in 2023 after having served as its CEO for over 16 years. Formerly known as Caprion Biosciences and headquartered in Montreal, Canada, CellCarta is a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry. CellCarta operates globally with over 900 employees in its 9 facilities located in Canada, the United States, Belgium, Australia and China.

Martin is also chairman of the board of directors of Saguaro Biosciences as well as a member of the board of directors of several other life sciences companies and a strategic advisor to 2 healthcare private equity funds.

Prior to co-founding Caprion, Martin was a management consultant for McKinsey & Company (1990-96), and then co-owner and senior executive of another successful biotech venture, Advanced Bioconcept (1996-2000) which was acquired by NEN Life Sciences (now Revvity) in 1998.

Martin earned his bachelor's degree in Economics from the Université de Moncton prior to completing a B.A/M.A. in Philosophy, Politics and Economics at Oxford University as a Rhodes Scholar.

Sanjay Voleti
CHIEF EXECUTIVE OFFICER and member of the board

Sanjay Voleti serves as Chief Executive Officer of Icentia, leading the company’s international growth and commercial expansion. With more than 20 years of global leadership experience across digital health, artificial intelligence, semiconductors, and consumer technology, Sanjay has a proven track record of scaling technology businesses and driving market adoption worldwide.

Prior to joining Icentia, Sanjay was Co-Founder and CEO of Adventyx and previously served as Chief Strategy Officer and Chief Business Officer at AliveCor, where he led strategy, partnerships, and global expansion of AI-powered ECG solutions. Earlier in his career, he held leadership roles at Amazon and Texas Instruments.

Sanjay holds an MBA from Rice University’s Jones Graduate School of Business, where he was a Jones School Fellow, and a B.S. in Electrical Engineering from Texas A&M University.

PIERRE PAQUET
CHIEF Product OFFICER and member of the board

Pierre Paquet serves as Chief Product Officer at Icentia, where he leads product strategy, innovation, and development. As a co-founder of Icentia, Pierre served as Chief Executive Officer from the company’s founding in 2012 until 2026, leading the development and international growth of the company and playing a key role in the evolution of CardioSTAT.

Prior to joining Icentia, Pierre was Director of Product Management for the Innovation Center at CareFusion, a San Diego-based global healthcare company. Previously, he served as Director of Implantable Devices in the field of active neurological implants at Victhom Human Bionics.

Pierre holds a B.S. in Mechanical Engineering from Laval University and an M.B.A. in Management of Technology from the Swiss Federal Institute of Technology in Lausanne, Switzerland.

Sean Karamchandani
member of the board

Sean Karamchandani is Investment Director in the Canadian venture capital arm of Crédit Mutuel Equity, a private equity subsidiary of Crédit Mutuel Alliance Fédérale, one of France’s largest banking organizations.

With 10 years of experience in healthcare investment in both venture and growth-equity Sean began his career as a management consultant to large healthcare institutions. He was then a partner with Persistence Capital Partners, a Canadian healthcare focused private-equity fund. Sean has dedicated his career to accelerating healthcare service, device, product, and pharmaceutical companies. .

Sean holds a bachelor’s degree in economics from Harvard University and an MBA from Columbia Business School in New York.

Louis Laflamme
member OF THE BOARD

Louis Laflamme is President and Chief Executive Officer of Antegrade Medical Inc. He also serves on the boards of LSL Pharma, Emka TECHNOLOGIES, MY01 IP Holdings Inc., Icentia, and SiliCycle.

Louis spent nearly two decades at OpSens, joining the company in 2005 as Chief Financial Officer. In 2013, he became President and Chief Executive Officer, a position he held until the company was acquired by Haemonetics in 2023 for USD 345 million. Under his leadership, OpSens achieved significant growth and established itself as an innovative medical technology company focused on fiber optic sensing technologies for interventional cardiology and structural heart applications.

With more than 20 years of experience in management and corporate governance, Louis brings extensive expertise in finance, strategy, business development, and the growth of medical technology companies.

Louis has been a member of the Ordre des comptables professionnels agréés du Québec since 2001. He holds a Bachelor of Business Administration from Laval University, which he obtained in 1998.

RICHARD BORDELEAU
member OF THE BOARD

Richard Bordeleau is currently CEO of Anasens, a medical device company developing a point-of-care therapeutic drug monitoring instrument based on nanotechnology. He brings extensive experience in healthcare, biotechnology, international commercialization, and financing.

After working as a consultant with several innovative companies, Richard held executive positions at Laboratoires Aeterna from 1994 to 1999, where he established partnerships with major pharmaceutical companies and played a key role in project financing. He subsequently served as President of Atrium Innovations from 2000 to 2007, leading the international launch and commercialization of specialty chemicals and nutritional products.

In 2007, Richard became a shareholder and director of BioCad Medical. Following BioCad’s acquisition by Nobel Biocare in 2009, he became an angel investor in startups across a range of sectors. He is also President of Fonds InnovExport, a $45 million fund dedicated to financing companies developing innovative products for international markets.

Richard holds a Bachelor’s degree in Business Administration from Université Laval and is a graduate of the Leading Strategy Program for Executives at HEC Paris.

YANNICK LE DEVEHAT
CHIEF TECHNOLOGY OFFICER

Yannick is a seasoned executive and entrepreneur with extensive experience in high-tech product design and manufacturing. During a 5-year posting in Tokyo, Japan, Yannick managed the Telecom and Smart Card Business Unit of TÜV SÜD, one of the world's largest product certification agencies. Since then, he has been active in the management of new tech-ventures, bringing in a wealth of experience in technology, supply chain management, and contract negotiation at an international level.

Yannick graduated with a B.S. degree in electrical engineering from Laval University.